Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study
作者： T. M. E. Davis , B. B. Yeap , W. A. Davis , D. G. Bruce
DOI: 10.1007/S00125-007-0919-2
关键词: Incidence (epidemiology) 、 Endocrinology 、 Type 2 diabetes 、 Cross-sectional study 、 Type 2 Diabetes Mellitus 、 Internal medicine 、 Fibrate 、 Diabetes mellitus 、 Statin 、 Medicine 、 Cohort study
摘要: Aims/hypothesis The aim of this study was to assess the relationships between lipid-lowering therapy and prevalence incidence peripheral sensory neuropathy in type 2 diabetes mellitus.
springer.com
paperity.org参考文章(11)
J. Schatanoff, T. G. Duncan, G. G. Duncan, F. A. Elliott, Some clinical potentials of chlorophenoxyisobutyrate (Clofibrate) therapy. (Hyperlipidemia--angina pectoris--blood sludging--diabetic neuropathy). Transactions of the American Clinical and Climatological Association. ,vol. 79, pp. 216- 228 ,(1968)
A. GIRACH, D. MANNER, M. PORTA, Diabetic microvascular complications: can patients at risk be identified? A review International Journal of Clinical Practice. ,vol. 60, pp. 1471- 1483 ,(2006) , 10.1111/J.1742-1241.2006.01175.X
Masaaki Ii, Hiromi Nishimura, Kengo F. Kusano, Gangjian Qin, Young-sup Yoon, Andrea Wecker, Takayuki Asahara, Douglas W. Losordo, Neuronal Nitric Oxide Synthase Mediates Statin-Induced Restoration of Vasa Nervorum and Reversal of Diabetic Neuropathy Circulation. ,vol. 112, pp. 93- 102 ,(2005) , 10.1161/CIRCULATIONAHA.104.511964
Ganesaratnam K. Balendiran, Balakrishnan Rajkumar, Fibrates inhibit aldose reductase activity in the forward and reverse reactions Biochemical Pharmacology. ,vol. 70, pp. 1653- 1663 ,(2005) , 10.1016/J.BCP.2005.06.029
Ali Moghtaderi, Alireza Bakhshipour, Homayra Rashidi, Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy Clinical Neurology and Neurosurgery. ,vol. 108, pp. 477- 481 ,(2006) , 10.1016/J.CLINEURO.2005.08.003
Giovanni Corrao, Antonella Zambon, Lorenza Bertù, Edoardo Botteri, Olivia Leoni, Paolo Contiero, Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases Journal of Epidemiology and Community Health. ,vol. 58, pp. 1047- 1051 ,(2004) , 10.1136/JECH.2003.013409
Peter Gæde, Pernille Vedel, Nicolai Larsen, Gunnar V.H. Jensen, Hans-Henrik Parving, Oluf Pedersen, Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes The New England Journal of Medicine. ,vol. 348, pp. 383- 393 ,(2003) , 10.1056/NEJMOA021778
T. M. E. Davis, P. Zimmet, W. A. Davis, D. G. Bruce, S. Fida, I. R. Mackay, Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi‐ethnic Australian community: the Fremantle Diabetes Study Diabetic Medicine. ,vol. 17, pp. 667- 674 ,(2000) , 10.1046/J.1464-5491.2000.00359.X
FIELD Study Investigators, None, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. ,vol. 366, pp. 1849- 1861 ,(2005) , 10.1016/S0140-6736(05)67667-2
K Benson, A.J Hartz, A comparison of observational studies and randomized, controlled trials American Journal of Ophthalmology. ,vol. 130, pp. 688- ,(2000) , 10.1016/S0002-9394(00)00754-6